EurekAlert! -- PHILADELPHIA — Despite strong evidence of its effectiveness, few of the young women who are eligible for the human papillomavirus (HPV) vaccine take it, according to research presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10. What’s more, many of the teens who begin treatment do not complete the recommended three-dose regimen.
